Loading clinical trials...
Loading clinical trials...
A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis
A study to assess the long-term safety of tacrolimus cream in the treatment of psoriasis
A long-term, open label, non-comparative, multi-center study to evaluate the safety of tacrolimus cream-B 0.1% in treating the signs and symptoms of psoriasis.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
Fresno, California, United States
Santa Monica, California, United States
Vista, California, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Newnan, Georgia, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Start Date
January 1, 2006
Primary Completion Date
August 1, 2007
Completion Date
August 1, 2007
Last Updated
February 13, 2008
658
ACTUAL participants
Tacrolimus Cream
DRUG
Lead Sponsor
Astellas Pharma Inc
Collaborators
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions